Barclays PLC Sage Therapeutics, Inc. Put Options Transaction History

Barclays PLC

12 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2024 May 15, 2024	BUY	$18.62 - $26.95 $55,860 - $80,850	3,000 Added 11.11%	30,000 $562,000
Q4 2023 Feb 15, 2024	BUY	$17.1 - $22.26 $461,700 - $601,020	27,000 New	27,000 $585,000
Q4 2019 Feb 10, 2020	SELL	$60.18 - $154.77 $746,232 - $1.92 Million	-12,400 Reduced 30.32%	28,500 $2.06 Million
Q3 2019 Nov 14, 2019	SELL	$140.29 - $189.96 $3.79 Million - $5.13 Million	-27,000 Reduced 39.76%	40,900 $5.74 Million
Q2 2019 Aug 14, 2019	BUY	$157.85 - $183.09 $8.33 Million - $9.67 Million	52,800 Added 349.67%	67,900 $12.4 Million
Q1 2019 May 15, 2019	SELL	$89.33 - $163.65 $6.41 Million - $11.8 Million	-71,800 Reduced 82.62%	15,100 $2.4 Million
Q4 2018 Feb 14, 2019	BUY	$81.94 - $139.71 $6.22 Million - $10.6 Million	75,900 Added 690.0%	86,900 $8.32 Million
Q3 2018 Nov 14, 2018	BUY	$138.11 - $169.04 $828,660 - $1.01 Million	6,000 Added 120.0%	11,000 $1.55 Million
Q2 2018 Aug 14, 2018	BUY	$140.36 - $175.76 $140,360 - $175,760	1,000 Added 25.0%	5,000 $783,000
Q1 2018 May 15, 2018	SELL	$152.15 - $192.33 $17.5 Million - $22.1 Million	-114,800 Reduced 96.63%	4,000 $644,000
Q4 2017 Feb 14, 2018	BUY	$60.72 - $167.34 $3.67 Million - $10.1 Million	60,400 Added 103.42%	118,800 $19.6 Million
Q3 2017 Nov 14, 2017	BUY	$61.4 - $88.52 $3.59 Million - $5.17 Million	58,400	58,400 $3.64 Million

198

46.5M

402K

209K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $326M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.